Address:
10-2155 Dunwin Dr.
Mississauga, ON L5L 4M1
CA
Mailling Address:
10-2155 Dunwin Dr.
Mississauga, ON L5L 4M1
CA
Phone:
(905) 569-2265
Fax:
(905) 569-9231
Email:
Click Here
Map it:
Click Here
Website:
http://www.vasogen.com
Vasogen Inc.
Vasogen is a leader in the research and commercial development
of immune modulation therapies for the treatment of
cardiovascular, neurological, and other chronic inflammatory
diseases. Vasogen's lead product, Celacade (immune modulation
therapy), utilizes proprietary medical device technology,
designed to target chronic inflammation by activating the immune
system's physiological anti-inflammatory response to cells
undergoing apoptosis (programmed cell death). Celacade is
currently in pivotal phase III clinical trials for the treatment
of chronic heart failure and peripheral arterial disease.
Vasogen is also developing a new class of drugs for the
treatment of additional indications, including neuro-
inflammatory diseases.
Company Details
Number of Employees:
80
Company Information
Glenn Neumann
Title:
Director of Investor Relations
Telephone:
(905) 569-9065
Fax:
(905) 569-9231
Email:
Click Here
David Elsley
Title:
President & C.E.O.
Telephone:
(905) 569-2265
Fax:
(905) 569-9231
Email:
Click Here
Chris Waddick
Title:
Executive Vice President & CFO
Telephone:
(905) 569-2265
Fax:
(905) 569-9231
Email:
Click Here
Products
Celacade (immune Modulation Therapy) For Peripheral Arterial Disease (pad)
Celacade (immune Modulation Therapy) For Chronic Heart Failure
Chronic HF, most frequently resulting from coronary artery
disease or hypertension, is a debilitating condition in which
the hearts ability to function as a pump is impaired. Patients
with HF experience a continuing decline in their health,
resulting in an increased frequency of hospitalization and
premature death. Vasogen is enrolling patients in its pivotal
phase III ACCLAIM trial in chronic heart failure, in support of
the regulatory approvals process. This 2,000-patient trial is
designed to demonstrate the ability of Celacade to reduce the
risk of death and hospitalization in patients with advanced
chronic HF. The initiation of the ACCLAIM trial was based on
Vasogens successful phase II trial conducted in 73 patients
with advanced chronic HF who were receiving the current standard
of care. The results of this study demonstrated a significant
reduction in the risk of death and hospitalization and
significant improvements in both key electrocardiogram measures
and a clinical composite score. Celacade was also shown to be
well tolerated, with no reports of treatment-related serious
adverse events or withdrawals from the trial. The Global
Principal Investigator and Chairman of the Steering Committee
for the ACCLAIM trial is Dr. James B. Young, Chairman, Division
of Medicine, The Cleveland Clinic Foundation and Medical
Director of the Kaufman Center for Heart Failure in Cleveland,
Ohio. Dr. Young has played a leading role in numerous multi-
center clinical trials focusing on heart failure and
transplantation, and is the author of many articles appearing in
journals such as The New England Journal of Medicine, Chest, and
The American Journal of Cardiology.
Services